LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

Search

Allogene Therapeutics Inc

Closed

SectorHealthcare

1.36 1.49

Overview

Share price change

24h

Current

Min

1.32

Max

1.4

Key metrics

By Trading Economics

Income

206K

-60M

EPS

-0.28

Profit margin

272,450

Employees

226

EBITDA

-302K

-56M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+479.85% upside

Dividends

By Dow Jones

Next Earnings

6 sie 2025

Market Stats

By TradingEconomics

Market Cap

53M

308M

Previous open

-0.13

Previous close

1.36

News Sentiment

By Acuity

50%

50%

164 / 381 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Allogene Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 cze 2025, 22:33 UTC

Acquisitions, Mergers, Takeovers

KKR to Acquire Australian Power Provider Zenith Energy

16 cze 2025, 21:55 UTC

Major Market Movers

Geospace Technologies Shares Up on Petrobras Pact

16 cze 2025, 17:04 UTC

Major Market Movers

Roku Shares Climb on Advertising Deal with Amazon

16 cze 2025, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 cze 2025, 23:51 UTC

Market Talk

Nikkei May Trade Range Bound Amid Israel-Iran Conflict -- Market Talk

16 cze 2025, 23:41 UTC

Market Talk

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

16 cze 2025, 23:10 UTC

Market Talk
Acquisitions, Mergers, Takeovers

XRG Has 'Viable Path' to Approval of Santos Takeover -- Market Talk

16 cze 2025, 23:02 UTC

Market Talk

Auckland Airport Unlikely to Hit Target for International Passengers -- Market Talk

16 cze 2025, 22:32 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Santos Unlikely to Attract Rival Bidder to XRG -- Market Talk

16 cze 2025, 22:03 UTC

Acquisitions, Mergers, Takeovers

KKR & Co. to Buy Zenith Energy From Consortium Including Pacific Equity Partners, OPSEU Pension Trust, Foresight Group >KKR

16 cze 2025, 22:00 UTC

Acquisitions, Mergers, Takeovers

KKR Acquires Leading Australian Independent Power Producer Zenith Energy >KKR

16 cze 2025, 21:56 UTC

Earnings

Lennar Has an Earnings Miss. The Stock Slips. -- Barrons.com

16 cze 2025, 21:10 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi in Talks to Sign $8 Billion Deal With Gas Producer Aethon -- WSJ

16 cze 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16 cze 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

16 cze 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 cze 2025, 20:49 UTC

Market Talk

Fitch Revises Canadian Provinces Fiscal Outlook to 'Deteriorating' -- Market Talk

16 cze 2025, 20:14 UTC

Acquisitions, Mergers, Takeovers

Update: EchoStar Stock Surges. It's Short Covering and President Trump. -- Barrons.com

16 cze 2025, 20:13 UTC

Market Talk

Natural Gas Gains on Warmer Outlook -- Market Talk

16 cze 2025, 19:58 UTC

Acquisitions, Mergers, Takeovers

OpenAI and Microsoft Tensions Are Reaching a Boiling Point -- WSJ

16 cze 2025, 19:13 UTC

Market Talk

Middle-East Conflict May Not Push Up Oil Long Term -- Market Talk

16 cze 2025, 19:09 UTC

Market Talk

Amazon-Roku Deal Shows Competition for Streaming Ad Space -- Market Talk

16 cze 2025, 18:43 UTC

Market Talk

May Could Mark Nascent Recovery in Canada Housing Market -- Market Talk

16 cze 2025, 18:36 UTC

Market Talk

Soybeans May Get Boost from Renewable Fuel Obligations -- Market Talk

16 cze 2025, 18:29 UTC

Market Talk

Global Equities Roundup: Market Talk

16 cze 2025, 18:29 UTC

Market Talk

Shopify Appears More Resilient Than Feared -- Market Talk

16 cze 2025, 18:22 UTC

Market Talk

Citi Forecasts Downturn in Gold Futures -- Market Talk

16 cze 2025, 16:42 UTC

Market Talk

Homebuyers' Downpayments Are Shrinking For First Time in 2 Years -- Market Talk

16 cze 2025, 16:37 UTC

Market Talk

Big, Beautiful Bill Might Not Mean Big Growth -- Market Talk

16 cze 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Peer Comparison

Price change

Allogene Therapeutics Inc Forecast

Price Target

By TipRanks

479.85% upside

12 Months Forecast

Average 7.77 USD  479.85%

High 14 USD

Low 2.5 USD

Based on 14 Wall Street analysts offering 12 month price targets forAllogene Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

11

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

1.18 / 1.69Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

164 / 381 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.